Stockholders’ Deficit (Details) - USD ($)				1 Months Ended						6 Months Ended
	Jul. 15, 2021	Feb. 02, 2021	Nov. 10, 2015	Jun. 22, 2021	Mar. 31, 2021	Mar. 29, 2021	Mar. 23, 2021	Mar. 19, 2021	Feb. 28, 2021	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Nov. 21, 2017	Dec. 31, 2015
Stockholders’ Deficit (Details) [Line Items]
Common stock, authorized										100,000,000	100,000,000
Preferred stock, authorized															15,000,000
Capital stock, description			the Company’s authorized capital stock consisted of 100 million shares of common stock, $.001 par value, and 10 million shares of preferred stock, $.001 par value.
Common stock, shares, issued										12,185,496	5,099,512
Common stock share outstanding										12,185,496	5,099,512
Shares issued in connection with registered direct offering									4,388,854
Sale of Stock, Consideration Received on Transaction (in Dollars)									$ 8,898
Aggregate shares					1,975,000
Net proceeds (in Dollars)	$ 8,000				$ 3,523					$ 20,951
Exercise of common stock warrants					701,179
Restricted Stock, Shares Issued Net of Shares for Tax Withholdings					1,220
Warrant to purchase shares										4,553,234		2,582,697	489,176
Common stock, par value (in Dollars per share)										$ 0.001	$ 0.001
Aggregate shares of common stock								700,680
Registered direct offering, description							On March 23, 2021, the Company consummated a registered direct offering with certain institutional investors and issued an aggregate of 1,975,000 shares of the Company’s common stock, par value $0.001 per share at a purchase price of $2.00 per share for gross proceeds to the Company of approximately $3.95 million, pursuant to a prospectus, dated August 24, 2018, and a prospectus supplement, dated March 22, 2021, in connection with a takedown from the Company’s shelf registration statement on Form S-3 (File No. 333-225712).
Shares of commons stock for the exercise				499
Placement Agent Warrants [Member]
Stockholders’ Deficit (Details) [Line Items]
Shares issued in connection with exercise of warrants										148,125
Exercise price per share (in Dollars per share)										$ 2.50
Common Stock [Member]
Stockholders’ Deficit (Details) [Line Items]
Common stock, authorized			100,000,000
Common stock, shares, issued										7,085,984
Private Placement [Member]
Stockholders’ Deficit (Details) [Line Items]
Warrant to purchase shares		3,968,854
Common stock, par value (in Dollars per share)		$ 0.001
Purchase price per share (in Dollars per share)		$ 2.2785
Aggregate shares of common stock		420,000
Purchase price of pre- funded warrants (in Dollars per share)		$ 2,277.5000
Shares issued in connection with exercise of warrants		2,194,427
Gross proceeds (in Dollars)		$ 10,000,000.0
Exercise price per share, description						all 420,000 pre-funded shares had been distributed. In connection with the offering, we issued the placement agent warrants to purchase up to 329,164 shares of Common Stock with an exercise price of $2.8481 per share.
Public Offering [Member]
Stockholders’ Deficit (Details) [Line Items]
Net proceeds (in Dollars)										$ 1,220,000
Shares issued in connection with exercise of warrants														293,000
Series A Convertible Preferred Stock [Member]
Stockholders’ Deficit (Details) [Line Items]
Preferred stock, authorized			2,000,000
Preferred stock, par value (in Dollars per share)			$ 0.001
Series B Convertible Preferred Stock [Member]
Stockholders’ Deficit (Details) [Line Items]
Preferred stock, authorized															7,515,000